Safeguard Scientifics Inc (SFE) 2011 Q1 法說會逐字稿

Good day, ladies and gentlemen, and welcome to your Safeguard Scientifics first quarter and 2011 results conference call. (Operator Instructions) And as a reminder this is being recorded. I would now like to introduce Mr. John Shave, Vice President of Business Development and Corporate Communications. You may begin.

Good morning and thank you for joining us for our first quarter financial results conference call and update. Joining me on today's call are Peter Boni, Safeguard's President and Chief Executive Officer, and Steve Zarrilli, Senior Vice President and Chief Financial Officer. During today's call Peter will review first quarter 2011 highlights and other developments. Then Steve will discuss Safeguard's financial results and strategies. After that, we'll open up the lines for your questions.

Before we begin, I must remind you that today's presentation includes forward-looking statements. Reliance on forward-looking statements involve certain risks and uncertainties, including future performance of our partner companies, the risks of acquisition or disposition of interest in partner companies, capital spending by customers, regulatory and economic conditions generally, as well as the development of the life sciences and technology markets and other uncertainties that are described in our SEC filings.

During the course of today's call, words such as "accept"," anticipate", "believe", and "intend" will be used in our discussion of goals or events in the future. Management cannot be certain that final outcomes will be as described today. We encourage you to read Safeguard's filings with the SEC, including our Form 10-K. The Company does not assume any obligation to update forward-looking statements made today.

Now here is Safeguard's President and CEO, Peter Boni.

Thanks, John, and thank you all for joining us today for updates on Safeguard Scientifics and our partner companies. The results for the first quarter ending March 31st were distributed early today. We're encouraged by advances across several fronts of our strategic game plan.

First, we continued to drive aggressive growth and milestone achievements in our partner companies. Specifically, we provided $9.0 million of follow-on funding to technology company, MediaMath, in part to expand global sales and marketing initiatives and then to fuel technology development.

Next, we deployed $5.0 million of equity capital into ThingWorx, an innovative technology partner company that is addressing a growing market in managing data from connected devices. And then subsequent to the quarter, we deployed $25 million of equity capital into PixelOptics, a medical technology company that's developed and will soon be commercializing the world's first and only electronically-focusing prescription eyewear. I'll talk more about MediaMath and PixelOptics a bit later.

Lastly, we took our first substantial step towards our strategic initiative of augmenting Safeguard's existing resources with alternative sources of capital. Safeguard reached an agreement in principle to acquire a significant equity interest in an operating and management enterprise of a mezzanine lending company and to commit a total of $30 million of capital to such venture over several years. The strategic partnership will be formed with a private company which provides subordinated debt and structured equity financing.

Our capital will be deployed alongside private capital committed to funds managed by the company. It's anticipated that, initially, the firm will have in excess of $60 million available for lending and operations, including our capital and committed capital from a few limited partners. This entity will deploy capital principally in subordinated debt financing for lower middle-market enterprises operating generally in the Mid-Atlantic region, as well as other geographies strategic to Safeguard.

This initiative not only allows us to directly augment our available capital, but also squarely positions Safeguard with an advantage to address both equity and debt capital needs of enterprises. The mezzanine company will be managed by an experienced team of subordinated debt lenders and together, we will be able to ramp up operations quickly.

For some time now, we've stated that we've been working towards to develop an approach to leverage alternative pools of capital. We see a gaping opportunity to provide capital to both private and public enterprises in small-to-mid markets. This initiative will augment what we already do - provide meaningful and flexible capital, plus operational support services, to growth-stage businesses.

As an equity partner in this mezzanine lending enterprise, we'll have expanded our platform and created a framework, which we intend to replicate, to take advantage of other opportunities to leverage other sources of capital and external management expertise in a fashion that produces income and profit participation for the Company.

This initiative furthers Safeguard's capability and enhances our strategy to seek equity or debt positions, via significant minority or majorly stakes, in public or private companies, with our own capital and managed capital from strategic and financial sources. Steve will provide some further detail later on, on the call and then we'll announce the name under which the joint venture will operate and other details of the transaction at a future date.

In the meantime, looking more broadly at external US factors, the US economy continues a slow recovery after the 2008 nosedive, but moreover, positive momentum in global capital markets continues, despite any instability in the Middle East or Northern Africa and despite any natural disasters in Japan.

First quarter M&A and IPO headlines were mixed, while proceeds from 32 IPO transactions totaling over $12 billion, the highest first quarter value since 2008 according to data complied by PWC. They couldn't keep pace with activity in Q4 2010 but were ahead of a year ago. Excluding the Visa IPO in 2008, the largest IPO in US history, 2011's first quarter proceeds overall were the biggest since 2000. The US IPO market is thought to be on pace to generate more than $39 billion in 2011, far eclipsing the 2011 annual total.

Trends in deal volume and value are encouraging for entrepreneurs and financial sponsors alike, signaling improved access to capital for businesses and good liquidity for investors. Included in the current IPO pipeline are 44 venture-backed firms and one of those 44 is Safeguard's life sciences partner company, Advanced BioHealing.

Today, Safeguard's growth stage, life science, and technology partner companies remain well positioned for continued growth and improved profitability. Our deal teams continue to evaluate promising high potential businesses in our target verticals and our optimism is really high for creating additional value for not only 2010, but beyond.

The confidence stems from Safeguard's disciplined focus on specific segments within the life sciences and technology industries that exploit five strategic themes that drive growth - maturity, migration, convergence, compliance, and cost containment. We typically deploy up to $25 million in growth capital per company and then time our exits from ownership positions in these companies to achieve aggregated target, risk-adjusted returns of capital of three-to-five times.

Exit opportunities may arise at any time and in different forms, including privately negotiated sale of securities or assets, public offerings of securities, or in the case of a publically traded partner company, the sale of securities on the open market. If an opportunity clears our strategic growth and return arrows, we'll respond appropriately.

We will not deploy capital or pursue exits simply for activity's sake. We have said this often and we can't say it enough. Discipline is the hallmark of the Safeguard strategy. In the meantime, we'll continue to work to build value in Safeguard's partner companies, drive their growth and keep their spending plans in line.

The addition of PixelOptics to the Safeguard's roster of life sciences partner companies is especially exciting. Subsequent to the first quarter's close, we announced our lead role in a $45 million equity and debt financing round for PixelOptics. Safeguard deployed $25 million of the $35 million raise for a 25% ownership stake. Now the civic partners for the equity financing included Delphi Ventures, the Carlyle Group, Longitude Capital, and Stark Investments, while Horizon Technology Finance provided the $10 million of venture debt.

Now Pixel is a medical technology company that has developed and will soon be commercializing the world's first and only electronically-focused prescription eyewear called "emPower!" This innovative company is changing the standard of eye care for eyeglass wearers. PixelOptics' novel approach to vision correction is really revolutionizing how eyeglass wearers will be able to transition between near and far distances.

The company's product emPower! represents the most significant technological advance in prescription eyewear in the last 50 years. Featuring the most advanced electronic innovations, emPower! substantially reduces or eliminates the perceived distortions and other limitations associated with multi-focus lenses. It will be addressing a really large, growing, $13 billion global market, with a highly differentiated and innovative product. We welcome PixelOptics to the Safeguard team and are looking forward to providing you with updates on our next call.

Now let's review some specific recent developments at some of our partner companies that underscore the power of Safeguard's business model. As noted, the life sciences partner company, Advanced BioHealing, has filed their registration statement on Form S-1 statement with the SEC in preparation for its IPO. Safeguard deployed $10.8 million of capital in ABH since February of 2007 and we have a 28% ownership stake. Because of the pending transaction, I can't add much more, but please refer to the ABH filings with SEC.

Progress continues at NuPathe, which is in the specialty pharmaceuticals vertical. NuPathe recently gained FDA acceptance of its New Drug Application for its lead product candidate, Zelrix, a single-use transdermal patch for the treatment of acute migraine. The company expects the FDA to complete its review of the NDA in third quarter of this year. Zelrix is the first ever submission to the FDA of a transdermal patch for migraine treatment. The commercial launch of Zelrix is forecast by the company to occur in the first half of next year.

In late 2010, NuPathe raised $43 million of net proceeds from its IPO, boosting its cash reserves. Safeguard has deployed $18.3 million of capital in NuPathe since September of 2006 and we own 18% of its outstanding common shares.

Our healthcare IT companies, Advantage Healthcare Solutions and Portico Systems, achieved continued growth during the quarter. The sector also continues to be a hotbed of acquisition activity for strategic and financial buyers alike.

AHS is now one of nation's top ten providers of medical billing and practice management services for physicians, ambulatory surgical centers, and other healthcare providers. The company's state of the art technology efficiently collects financial information and then accelerates the reimbursement of third-party claims and patient payments, enabling hospital physician groups to maximize revenue and decrease their billing of practice management costs.

AHS is achieving profitable growth. 2010 revenue was up almost 115% from 2009. With the completion of another acquisition late last year, AHS expects continued growth in 2011. Safeguard deployed $15.3 million of capital in AHS since November of 2006 for a 40% ownership stake.

Portico Systems offers provider management software and services to the health insurance industry that enables them to design, build, service, manage, and reimburse their provider networks. Portico has 39 healthcare insurance companies today, including Sigma, the Principal Financial Group and many of the big blues who serve more than 42 million members.

During the fourth quarter of last year, Safeguard provided Portico with a $5.0 million mezzanine debt financing, while the company also increased its credit facilities with Comerica Bank. Portico is using this financing to fuel the next level of market penetration. Company revenues have grown at double-digit rates over the past five years.

AlwaysOn, a follower of the field, previously named the firm in its OnDemand 100 for its innovation, market potential, commercialization, stakeholder value, and its media buzz. Based on Q1 performance, Portico has advanced from our expansion stage to our high-traction stage. Safeguard deployed a little over $14 million in Portico since August of 2006 and we have a 45% stake in the company.

Within the Internet and new media companies, growth at MediaMath has especially impressive. 2010 revenue was up 150% from the previous year and its demand continues to build for MediaMath; its enterprise-class digital media buying and reporting platform that enables advertising agencies and advertisers to analyze billions of daily impressions.

In 2010, MediaMath made key strategic hires and it acquired Adroit Interactive. Its continued momentum reflects the environment for digital display advertising. The Interactive Adverting Bureau featured in an annual report prepared by TWC that, for the first time ever in 2010, display ad spend exceeded newspaper advertising spend. Web ad revenue rose 15% to $26 billion and that growth was led by a 24% gain in display advertising, like online banner ads, digital video ads - all a sign that major brands are growing more comfortable with the medium as a place to invest their marketing dollars.

This supports one of our major themes - migration - demonstrating that consumers and businesses are migrating from off-line to online for news, advertising, and other forms of media. The Company has been aggressively growing its domestic and international operations, opening offices in LA, Chicago, Boston and DC in the US and then in Ontario, Canada and in London. Additional offices are slated to launch this year in Latin America and then Asia.

As a result of this momentum, MediaMath was recognized by AlwaysOn for the third consecutive year as one of the hottest companies in the digital ad space and it's now ranked among the world's top 100 privately-held firms. In total, Safeguard has deployed $15.7 million at MediaMath since 2009 for a 22% primary ownership position.

Now, there's no shortage of progress throughout Safeguard's other partner companies, but in the interest of time, I'll stop there and I'll turn the call over to our CFO, Steve Zarrilli for an update on Safeguard's financial strategies and our performance. Go ahead, Steve

Thanks, Peter. I can elaborate on details of our financial, our strategic initiatives during the Q and A period. Until then, I want to outline big-picture trends in our performance and strategic objectives. The past two quarters at Safeguard have been periods of exceptional financial activity and achievement. Consider the following.

We realized big gains through the fourth quarter exit transactions involving Clarient and Avid Radiopharmaceuticals. We deployed some of that capital for ownership positions in promising new partner companies, ThingWorx and PixelOptics. In addition, in connection with the mezzanine lending initiative that Peter mentioned earlier, we will commit $30 million of capital, which will be actually deployed over a several-year period.

Further, we repurchased at face value substantially all of Safeguard's 2.625% convertible senior subordinated notes due in 2024. The repurchase reduced the debt-to-equity ratio to 1 to 5, from 1 to 3, at December 31, 2010, and 1 to 2 at December 321, 2009. Moreover, we have improved the match of our long-term obligations, with exit expectations and cash deployment plans.

Safeguard's debt balance at March 31st was $46.9 million in face value of the 10.125% convertible senior debentures due in March of 2014 and just over $400,000 in face value of our 2.625% convertible senior debentures.

Today Safeguard continues to enjoy financial strength and flexibility, with excellent liquidity and access to capital. Without fear of contradiction, we can say that Safeguard is stronger, leaner and better positioned to execute our game plan than in any other time over the last five years. This team's focus on value creation in keen and our optimism about Safeguard's prospects are real.

At March 31, 2011, we had $174 million in cash, cash equivalents, and marketable securities, excluding cash held in escrow of $6.4 million and restricted case equivalents of $14.5 million. In the first quarter, primary uses of cash were the repurchase of $30.8 million of our 2024 convertible senior debentures; cash operating expenses of $7.7 million. This total includes cash bonuses related to 2010 and excludes interest, non-cash stock-based compensation and depreciation expense.

For the year, we anticipate cash operating expenses in the range of $17 million to $18 million. That range reflects the addition of experienced field team professionals, as well as certain anticipated corporate development expenses. We also deployed $9.0 million into MediaMath and deployed $5.0 million into a new technology partner company, ThingWorx.

As you may recall, on our last quarterly conference call we said we expect to use between $100 million and $150 million in cash in 2011, specifically for the repayment of convertible senior debentures, corporate expenses, capital deployment into new partner companies, follow-on funding for current partner companies and the expansion of our platform.

The mezzanine lending initiative represents one facet of our strategy to leverage alternative sources of capital to expand our platform. Together, with the team at the mezzanine company, we intend to provide rational levels of debt and equity capital to the lower middle-market enterprises principally operating in the Mid-Atlantic region and secondarily, other geographies that Safeguard considers strategic.

Our role as an anchor partner in this enterprise serves to emphasize our commitment to develop this initiative. Here's an outline of some of the basic elements of the strategic partnership. We will announce further details regarding this relationship at a future date, when the definitive agreements are executed.

Safeguard will maintain a significant equity interest in the management enterprise of the company and will participate on the governing boards as we do with all of our partner companies. Safeguard will initially provide between $3.0 million and $4.0 million of working capital to the management company to fund, in part, its operations.

Safeguard will also commit to provide up to $27 million of additional funding over several years, to be deployed alongside private capital otherwise committed to the company's first fund in situations that meet certain predefined criteria.

It is anticipated that the initial capital of the company's fund will be deployed over a two-to-three-year period of time. Safeguard will provide support for the analysis of deployment opportunities based on the knowledge of areas of expertise within our management team. Safeguard will benefit from the management fees and profit participation earned from the private funds managed by the company.

The company intends to raise additional private capital in a fund-structured format, as the initial funds of the enterprise are fully deployed. Safeguard has committed to roll over its commented capital to be deployed alongside future private capital raised, subject to the enterprise producing certain pre-to-term minimum returns for Safeguard and Safeguard's significant deal pipeline will be used to augment the pipeline activities of the operation.

Broadly, this initiative is important to Safeguard for four primary reasons - capital and market expansion, pipeline synergy, asset diversification and income generation. Our pipeline is flush with interesting opportunities. We continue to focus on specific life science opportunities in the areas of lower relative technological and regulatory risk, namely in the molecular and point-of-care diagnostics, medical devices, regenerative medicine, specialty pharmaceuticals and selective healthcare services.

In technology, we still pursue transactions enabling applications with a recurring revenue business model in Internet and new media, financial technology, healthcare IT and other selected business services. Our deal teams are actively evaluating the potential for several new capital deployments over the near-term.

We may also find and opportunity or two in a later stage firm generally defined as a lower middle-market opportunity. The cash on cash return target for these later-stage deals may be two-to-three times versus our current three-to-five times cash on cash right, but the anticipated time horizon may be shorter as well.

We believe that Safeguard and its partner companies remain well positioned for continued revenue traction and value creation in 2011 and beyond. For 2011, Safeguard projects aggregate partner company revenue for its technology group to be in the range of $180 million to $190 million. Given the performance of our technology partner companies in Q1, they are on track to meet this target guidance.

For the life science group, due to Advanced BioHealing's registration statement on Form S-1 filing with the US SEC for an initial public offering, we are unable to provide aggregate partner company guidance for our life sciences group at this time. As a reminder, Safeguard reports the revenue of its partner companies on a one quarter lag.

Our partner companies continue to execute aggressively, are using their cash to grow and in some cases, generating cash and making strategic and opportunistic acquisitions. Our partner companies closed multiple acquisitions in 2010 and remain opportunistic to make additional acquisitions, either strategically or tactically, in 2001 as well.

We work with the management teams of our partner companies to evaluate levels of existing and required capital, strength in personnel resources and unique opportunities for growth. These ongoing processes allow us to assist management in unique ways to continually drive value creation and maturity.

With that, I'm going to turn it back over to Peter and we'll open it for Q and A.

Great. Thanks, Steve. Mary, let's open the phone for any questions.

Thank you (Operator Instructions) Greg Mason, Stifel Nicolaus

Great, thanks guys. My first question is about the fund. I know you'll announce the team and everything later, but can you give us a sense of how long this team has been doing mezzanine type of investments and given it's a $60 million fund, what's kind of the target hold size for your investments in that fund?

Steve, would you take that?

Greg, the team itself has well over 15 years of experience, much of that working together as a team about --?

Fifteen each.

Fifteen each, right, and obviously having spent a fair amount of time in this segment of the market. So we're very, very pleased with the opportunity to be able to partner with this dedicated and experienced team.

With respect to the second question, though, we're still at a point where we can't say a whole lot about the specifics of the company until we get to our definitive agreement. The target size of the investment will be somewhere in the $4.0 million to $6.0 million range.

And then just to clarify, are they doing kind of venture capital lending? Or is this kind of private equity, middle market debt?

This is more along the lines of typical mezzanine lower middle-market, subordinated debt.

Okay, great and then moving on. You gave us guidance for the technology revenues and I think this is maybe the first time that they've been broken out or that I remember. Can you give us some kind of historical track record or maybe what those numbers were over the last three years so we can get a sense for the growth in the tech revenue guidance?

Yes, sure, Greg. We have broken this out. We've given aggregate guidance and we have also given it by sector, life sciences and technology. In 2007, on an apples to apples basis, those companies did $46 million. In 2008, $63 million and 2009 $87 million and the last year, 2010, it did $139 million. So the $180 million to $190 million guidance for 2011 is off of $139 million for 2010.

Okay, great and then on the new investment, PixelOptics, you said they're approaching commercialization. What is your expectation for timing of when that business starts generating revenues? How close are we to that?

I would think that the summer of 2011 provides the right opportunity for launch for Pixel.

Okay, great and then could you also talk about Molecular Biometrics? In your press release it says that it's been pulled from the market and will take substantial new funding. Are you providing that or looking at that? What should we think about your investment in that business?

Greg, we're evaluating the situation at Molecular Biometrics and have made no determination to date.

Can you give us any information about kind of what happened with the product?

It was a technological issue that needed to be addressed in order to redeploy the product in the marketplace.

Okay, okay, great and then one final question. You talked about the pipeline as robust, but can you maybe give us a little more guidance about what you're seeing? Is it life science? Is it technology? Where are the most attractive opportunities you're seeing today for future investment?

Greg, across the board we're seeing some very attractive opportunities and in substantial numbers. Remember, we've been evaluating some thousand opportunities per year. We're definitely on track within that pace or maybe even excess of that pace to date.

During the financial meltdown of the last couple of years, a number of companies just took to the bunkers and they sequestered themselves and said, "Man, its hostile out there, we're going to just try to make it on our own for now." And what we see, as the economy is improving and the global markets are improving, they're taking their head out of the bunkers and saying, "My gosh, now we really need growth capital in order to execute a strategic game plan". So we're seeing a lot of activity across the board.

Great. Thanks, guys.

Thank you. (Operator Instructions) Matt Dolan, ROTH Capital Partners

Hi guys, good morning.

Good morning, Matt.

Hi Matt.

First question, a follow up on the mezzanine front and you touched on some of this. But, Steve, could you just maybe give us a little more on Safeguard's role in the management and operations of the fund? How much are you dedicating, from a spend perspective, to this fund? And then, secondly, I heard you say cash-on-cash return of two-to-three times. Is that your target across the board for the fund or is that for certain situations and maybe kind of calibrate us on return expectations within this initiative?

Great. So I think that there were three questions there. From an oversight and involvement perspective, like everything else that we do with our partner companies, we don't intend to be a passive participant in this platform. We actually anticipate being active in its governance.

There will be a dedicated team of professionals, experienced professionals who will be responsible for sourcing, evaluating and determining whether or not to go or no go on a particular opportunity. Most of those opportunities, given their anticipated size, though, will ultimately require some level of board approval as well and that has been baked into the review and approval process for that entity. So it's an active versus passive relationship.

With regard to cash-on-cash return targets, jumping to point number three, actually the way we're looking at this is from a mezzanine lending type of environment. Our cash-on-cash return expectations will probably be somewhere in the two-times cash-on-cash return range, but with a targeted IRR of something north of 20%.

Matt, I apologize. There was a middle question in there that you had asked.

Kind of just the -- it was just relative to you involvement and how much spend, if you could quantify that, as you raise your operating spend this year.

Well, it will not in any way impact our operating expense. This will be the capital that we're deploying into the fund, along with any other management fees that it may earn in connection with other private funds that are brought to bear, will more than sufficient to pay for the ongoing operations of that entity.

Where appropriate, we will leverage certain attributes and infrastructure elements of Safeguard to augment the fund's activities, but we don't expect that to be of any significant nature, nor should it have any substantial or significant impact on the projected operating expenses of Safeguard in and of itself.

Right. Great, okay, the second topic, in terms of deployment this year, by our math you're already closing in on $120 million in allocations. Should we think about things slowing down for Safeguard in terms of deployments for the remainder of 2011?

Well, also look at the mezzanine fund. I would encourage you to look at that as a multi-year deployment of capital, for one.

Sure.

So when you start to think about deployment of capital, we tend to look at that not at $30 million, necessarily in one year, but over a two-to-three-year period of time.

Right.

Again, we are very determined to put capital to work in the right opportunities that meet our criteria and we are currently on pace to stay within the guidance that we have provided before. Those two factors combined would suggest that we still have a fair amount of gunpowder or dry powder to be used in 2011 and we also expect that the capital that we have is more than sufficient to allow us to pursue the strategies outlined in our game plan for 2011.

Okay and then maybe one for Peter on exits. You touched on the IPO market and we saw big medical device acquisition last night announced. Can you give us your outlook for exit opportunities within your own portfolio? Are there any in the near-term that we should start thinking about?

I can't be predictive to that, Matt, except the environment is more attractive than its been over the last few years and we have a group of companies that continue to mature in their value creation.

Okay, that's really --.

Just to clarify, Matt, one of your questions. We still seek a three-to-five-times cash-on-cash return at a minimum, when we're seeking opportunities in those selected areas of technology and life sciences. What Steve mentioned is that the mez, that opportunity might be more along the lines of 2X and on occasion we might find a later-stage, lower middle market firm where we could put some capital to work and potentially look at two-to-three-times as a target, at a minimum.

So we have three-to-five, two, and then potentially a deal or two that's later-stage that might be two-to-three.

Right.

And just one point of clarity on the mez fund. The return of capital may be shorter as well. We might not -- we, in many cases, will not have to wait for a five-year period of time to transpire before that cash is recycled back into a newer opportunity.

Okay and then if I could sneak one more, a follow up on Pixel? It sounds like a summer 2011 launch. Anything beyond that, in terms of the aggressiveness of that launch and how we should start thinking about revenue contributions from that opportunity? Thanks a lot for the time.

Yes. Matt, I would encourage you to just continue to monitor that which is out in the public domain, as it relates to the marketing activities that Pixel has underway. It has gotten some very credible following in the marketplace as it relates to its technology and its appeal to the consumer marketplace. And the company is hoping to properly time the launch of its commercialization activities to ride the wave of excitement that's being built through its marketing and public relation activities.

Great. Thank you guys.

Also, Matt, Pixel will be penetrating and rollout regionally, giving it an opportunity to scale up its productions. So that's a regional rollout, not a global rollout, but it begins in the summer of this year.

Thanks a lot.

And we're really excited about it. That's a $13 billion market opportunity. There are some fifty million progressive lenses, globally, that have penetrated the marketplace. This is clearly a highly innovative product offering in that marketplace.

Does that answer your question?

Yes. Thanks a lot.

Okay. I am not showing any other questions at this time. I would now like to turn it back to the speakers for any additional remarks.

Okay, if there's no more questions. We will continue to give you outlines as to our capabilities as we've enhanced our strategy to seek equity or debt positions via significant minority or majority stakes, in private or public companies, with our own capital and managed capital from financial and strategic sources. We're excited about what we've done. We hope you are too and we'll continue to keep you posted on our progress. Thanks very much.

Ladies and gentlemen, this does conclude today's program You may now disconnect and have a wonderful day.